IPCA Laboratories climbed 6.24% to Rs 1073.40 after consolidated net profit surged 63% to Rs 193.54 crore on 26.86% rise in net sales to Rs 1,283.90 crore in Q2 September 2019 over Q2 September 2018.
Consolidated EBITDA before forex (gain)/loss rose 29% to Rs 282.99 crore in Q2 September 2019 over Q2 September 2018. Consolidated EBITDA margin stood at 21.79% in Q2 FY20 as against 21.37% in Q2 FY19.
Indian formulations income rose 16% to Rs 543.21 crore in Q2 September 2019 over Q2 September 2018. The exports income grew 27% to Rs 588.03 crore in Q2 September 2019 over Q2 September 2018.
The result was announced during market hours today, 7 November 2019.
Ipca Laboratories is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app